Back to Strategies
Full Throttle
CustomMassive growth which are trading at a fair price. Our full throttle approach focuses on businesses with explosive growth which are trading at a fair price relative to their expected future growth rate.
All criteria must pass
Revenue Growth (5Y) ≥ 15,0
Revenue Growth (1Y) ≥ 20,0
Debt/Equity 0,0 – 5,0
PEG Ratio 0,0 – 2,0
Matching Stocks (100)
Export CSV| Company | Score | Actions | ||
|---|---|---|---|---|
Travere Therapeutics, Inc.
TVTX
|
|
|
||
|
Revenue Growth (5Y)
38,9
(≥ 15,0)
Revenue Growth (1Y)
110,5
(≥ 20,0)
Debt/Equity
2,9
(0,0 – 5,0)
PEG Ratio
0,8
(0,0 – 2,0)
|
||||
XPeng Inc.
XPEV
|
|
|
||
|
Revenue Growth (5Y)
37,3
(≥ 15,0)
Revenue Growth (1Y)
82,6
(≥ 20,0)
Debt/Equity
1,2
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
Tempus AI, Inc.
TEM
|
|
|
||
|
Revenue Growth (5Y)
49,0
(≥ 15,0)
Revenue Growth (1Y)
83,4
(≥ 20,0)
Debt/Equity
1,7
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
Amprius Technologies, Inc.
AMPX
|
|
|
||
|
Revenue Growth (5Y)
126,5
(≥ 15,0)
Revenue Growth (1Y)
202,1
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
Abivax S.A.
ABVX
|
|
|
||
|
Revenue Growth (5Y)
261,8
(≥ 15,0)
Revenue Growth (1Y)
133,5
(≥ 20,0)
Debt/Equity
2,4
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Liquidia Corporation
LQDA
|
|
|
||
|
Revenue Growth (5Y)
87,3
(≥ 15,0)
Revenue Growth (1Y)
1031,2
(≥ 20,0)
Debt/Equity
4,4
(0,0 – 5,0)
PEG Ratio
0,8
(0,0 – 2,0)
|
||||
Tarsus Pharmaceuticals, Inc.
TARS
|
|
|
||
|
Revenue Growth (5Y)
67,7
(≥ 15,0)
Revenue Growth (1Y)
146,7
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
AnaptysBio, Inc.
ANAB
|
|
|
||
|
Revenue Growth (5Y)
38,8
(≥ 15,0)
Revenue Growth (1Y)
157,0
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Rhythm Pharmaceuticals, Inc.
RYTM
|
|
|
||
|
Revenue Growth (5Y)
178,5
(≥ 15,0)
Revenue Growth (1Y)
45,8
(≥ 20,0)
Debt/Equity
1,8
(0,0 – 5,0)
PEG Ratio
1,2
(0,0 – 2,0)
|
||||
JBT Marel Corporation
JBTM
|
|
|
||
|
Revenue Growth (5Y)
28,3
(≥ 15,0)
Revenue Growth (1Y)
121,3
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
WELL Health Technologies Corp.
WHTCF
|
|
|
||
|
Revenue Growth (5Y)
46,7
(≥ 15,0)
Revenue Growth (1Y)
52,1
(≥ 20,0)
Debt/Equity
0,8
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
MDA Space Ltd
MDA
|
|
|
||
|
Revenue Growth (5Y)
33,3
(≥ 15,0)
Revenue Growth (1Y)
58,5
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
argenx SE
ARGX
|
|
|
||
|
Revenue Growth (5Y)
70,1
(≥ 15,0)
Revenue Growth (1Y)
90,1
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,8
(0,0 – 2,0)
|
||||
Cronos Group Inc.
CRON
|
|
|
||
|
Revenue Growth (5Y)
31,6
(≥ 15,0)
Revenue Growth (1Y)
64,4
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,9
(0,0 – 2,0)
|
||||
AST SpaceMobile, Inc.
ASTS
|
|
|
||
|
Revenue Growth (5Y)
54,6
(≥ 15,0)
Revenue Growth (1Y)
1505,2
(≥ 20,0)
Debt/Equity
1,2
(0,0 – 5,0)
PEG Ratio
1,8
(0,0 – 2,0)
|
||||
Dutch Bros Inc.
BROS
|
|
|
||
|
Revenue Growth (5Y)
34,7
(≥ 15,0)
Revenue Growth (1Y)
27,9
(≥ 20,0)
Debt/Equity
1,6
(0,0 – 5,0)
PEG Ratio
0,9
(0,0 – 2,0)
|
||||
Construction Partners, Inc.
ROAD
|
|
|
||
|
Revenue Growth (5Y)
32,6
(≥ 15,0)
Revenue Growth (1Y)
54,2
(≥ 20,0)
Debt/Equity
1,9
(0,0 – 5,0)
PEG Ratio
1,8
(0,0 – 2,0)
|
||||
Lucid Group, Inc.
LCID
|
|
|
||
|
Revenue Growth (5Y)
165,8
(≥ 15,0)
Revenue Growth (1Y)
67,6
(≥ 20,0)
Debt/Equity
1,2
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Geron Corporation
GERN
|
|
|
||
|
Revenue Growth (5Y)
239,0
(≥ 15,0)
Revenue Growth (1Y)
138,8
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Palantir Technologies Inc.
PLTR
|
|
|
||
|
Revenue Growth (5Y)
30,5
(≥ 15,0)
Revenue Growth (1Y)
56,2
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Jiangsu Expressway Company Limited
JEXYY
|
|
|
||
|
Revenue Growth (5Y)
30,4
(≥ 15,0)
Revenue Growth (1Y)
52,7
(≥ 20,0)
Debt/Equity
0,5
(0,0 – 5,0)
PEG Ratio
0,7
(0,0 – 2,0)
|
||||
Telecom Argentina S.A.
TEO
|
|
|
||
|
Revenue Growth (5Y)
37,7
(≥ 15,0)
Revenue Growth (1Y)
123,9
(≥ 20,0)
Debt/Equity
0,6
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
FTAI Infrastructure Inc.
FIP
|
|
|
||
|
Revenue Growth (5Y)
43,0
(≥ 15,0)
Revenue Growth (1Y)
51,6
(≥ 20,0)
Debt/Equity
3,5
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
NVIDIA Corporation
NVDA
|
|
|
||
|
Revenue Growth (5Y)
68,3
(≥ 15,0)
Revenue Growth (1Y)
65,5
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
Viridian Therapeutics, Inc.
VRDN
|
|
|
||
|
Revenue Growth (5Y)
121,1
(≥ 15,0)
Revenue Growth (1Y)
23359,9
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,5
(0,0 – 2,0)
|
||||
Nutex Health, Inc.
NUTX
|
|
|
||
|
Revenue Growth (5Y)
27,5
(≥ 15,0)
Revenue Growth (1Y)
82,4
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
1,8
(0,0 – 2,0)
|
||||
CI&T Inc
CINT
|
|
|
||
|
Revenue Growth (5Y)
79,4
(≥ 15,0)
Revenue Growth (1Y)
511,0
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
TKO Group Holdings, Inc.
TKO
|
|
|
||
|
Revenue Growth (5Y)
44,2
(≥ 15,0)
Revenue Growth (1Y)
68,9
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
First Advantage Corporation
FA
|
|
|
||
|
Revenue Growth (5Y)
21,9
(≥ 15,0)
Revenue Growth (1Y)
83,0
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
IDEAYA Biosciences, Inc.
IDYA
|
|
|
||
|
Revenue Growth (5Y)
67,3
(≥ 15,0)
Revenue Growth (1Y)
3024,4
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,4
(0,0 – 2,0)
|
||||
Clearwater Analytics Holdings, Inc.
CWAN
|
|
|
||
|
Revenue Growth (5Y)
30,5
(≥ 15,0)
Revenue Growth (1Y)
61,9
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
1,6
(0,0 – 2,0)
|
||||
Evolv Technologies Holdings, Inc.
EVLV
|
|
|
||
|
Revenue Growth (5Y)
58,0
(≥ 15,0)
Revenue Growth (1Y)
40,5
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,9
(0,0 – 2,0)
|
||||
Gruma, S.A.B. de C.V.
GPAGF
|
|
|
||
|
Revenue Growth (5Y)
127,0
(≥ 15,0)
Revenue Growth (1Y)
1784,8
(≥ 20,0)
Debt/Equity
1,0
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Beam Therapeutics Inc.
BEAM
|
|
|
||
|
Revenue Growth (5Y)
28,1
(≥ 15,0)
Revenue Growth (1Y)
120,0
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,4
(0,0 – 2,0)
|
||||
Satellogic Inc.
SATL
|
|
|
||
|
Revenue Growth (5Y)
42,9
(≥ 15,0)
Revenue Growth (1Y)
37,6
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
Atour Lifestyle Holdings Limited
ATAT
|
|
|
||
|
Revenue Growth (5Y)
45,6
(≥ 15,0)
Revenue Growth (1Y)
31,3
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
Cadeler A/S
CDLR
|
|
|
||
|
Revenue Growth (5Y)
89,0
(≥ 15,0)
Revenue Growth (1Y)
129,0
(≥ 20,0)
Debt/Equity
0,5
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Aker ASA
AKAAF
|
|
|
||
|
Revenue Growth (5Y)
29,3
(≥ 15,0)
Revenue Growth (1Y)
82,0
(≥ 20,0)
Debt/Equity
0,7
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Innovative Aerosystems, Inc.
ISSC
|
|
|
||
|
Revenue Growth (5Y)
38,3
(≥ 15,0)
Revenue Growth (1Y)
78,6
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Xvivo Perfusion AB (publ)
XVIPY
|
|
|
||
|
Revenue Growth (5Y)
46,2
(≥ 15,0)
Revenue Growth (1Y)
37,6
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Grupo Gigante, S. A. B. de C. V.
GPGNF
|
|
|
||
|
Revenue Growth (5Y)
125,8
(≥ 15,0)
Revenue Growth (1Y)
2030,3
(≥ 20,0)
Debt/Equity
0,6
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Exchange Income Corporation
EIFZF
|
|
|
||
|
Revenue Growth (5Y)
23,4
(≥ 15,0)
Revenue Growth (1Y)
23,1
(≥ 20,0)
Debt/Equity
1,5
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
Eli Lilly and Company
LLY
|
|
|
||
|
Revenue Growth (5Y)
23,2
(≥ 15,0)
Revenue Growth (1Y)
44,7
(≥ 20,0)
Debt/Equity
1,6
(0,0 – 5,0)
PEG Ratio
0,5
(0,0 – 2,0)
|
||||
TG Therapeutics, Inc.
TGTX
|
|
|
||
|
Revenue Growth (5Y)
209,8
(≥ 15,0)
Revenue Growth (1Y)
87,3
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
TUI AG
TUIFF
|
|
|
||
|
Revenue Growth (5Y)
56,5
(≥ 15,0)
Revenue Growth (1Y)
22,5
(≥ 20,0)
Debt/Equity
2,5
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Lexicon Pharmaceuticals, Inc.
LXRX
|
|
|
||
|
Revenue Growth (5Y)
259,6
(≥ 15,0)
Revenue Growth (1Y)
60,2
(≥ 20,0)
Debt/Equity
0,6
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Applied Optoelectronics, Inc.
AAOI
|
|
|
||
|
Revenue Growth (5Y)
21,2
(≥ 15,0)
Revenue Growth (1Y)
82,8
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
Zymeworks Inc.
ZYME
|
|
|
||
|
Revenue Growth (5Y)
41,2
(≥ 15,0)
Revenue Growth (1Y)
38,9
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,7
(0,0 – 2,0)
|
||||
Türk Telekomünikasyon Anonim Sirketi
TRKNY
|
|
|
||
|
Revenue Growth (5Y)
66,4
(≥ 15,0)
Revenue Growth (1Y)
62,6
(≥ 20,0)
Debt/Equity
0,6
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
4DMedical Limited
FDMDF
|
|
|
||
|
Revenue Growth (5Y)
127,9
(≥ 15,0)
Revenue Growth (1Y)
91,9
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Ouster, Inc.
OUST
|
|
|
||
|
Revenue Growth (5Y)
49,9
(≥ 15,0)
Revenue Growth (1Y)
52,5
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,4
(0,0 – 2,0)
|
||||
EVgo, Inc.
EVGO
|
|
|
||
|
Revenue Growth (5Y)
103,9
(≥ 15,0)
Revenue Growth (1Y)
49,6
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
0,4
(0,0 – 2,0)
|
||||
Koç Holding A.S.
KHOLY
|
|
|
||
|
Revenue Growth (5Y)
71,4
(≥ 15,0)
Revenue Growth (1Y)
29,1
(≥ 20,0)
Debt/Equity
2,2
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Delivery Hero SE
DELHY
|
|
|
||
|
Revenue Growth (5Y)
49,3
(≥ 15,0)
Revenue Growth (1Y)
23,7
(≥ 20,0)
Debt/Equity
2,2
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Paymentus Holdings, Inc.
PAY
|
|
|
||
|
Revenue Growth (5Y)
31,9
(≥ 15,0)
Revenue Growth (1Y)
37,3
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
1,3
(0,0 – 2,0)
|
||||
Vital Farms, Inc.
VITL
|
|
|
||
|
Revenue Growth (5Y)
30,6
(≥ 15,0)
Revenue Growth (1Y)
25,3
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Cal-Maine Foods, Inc.
CALM
|
|
|
||
|
Revenue Growth (5Y)
33,3
(≥ 15,0)
Revenue Growth (1Y)
83,2
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Amphenol Corporation
APH
|
|
|
||
|
Revenue Growth (5Y)
20,7
(≥ 15,0)
Revenue Growth (1Y)
51,7
(≥ 20,0)
Debt/Equity
1,2
(0,0 – 5,0)
PEG Ratio
0,5
(0,0 – 2,0)
|
||||
Smurfit Westrock Plc
SW
|
|
|
||
|
Revenue Growth (5Y)
28,2
(≥ 15,0)
Revenue Growth (1Y)
38,8
(≥ 20,0)
Debt/Equity
0,7
(0,0 – 5,0)
PEG Ratio
0,5
(0,0 – 2,0)
|
||||
CBIZ, Inc.
CBZ
|
|
|
||
|
Revenue Growth (5Y)
25,7
(≥ 15,0)
Revenue Growth (1Y)
52,1
(≥ 20,0)
Debt/Equity
1,0
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Sanrio Company, Ltd.
SNROF
|
|
|
||
|
Revenue Growth (5Y)
37,1
(≥ 15,0)
Revenue Growth (1Y)
44,9
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
Ceres Power Holdings plc
CPWHF
|
|
|
||
|
Revenue Growth (5Y)
25,2
(≥ 15,0)
Revenue Growth (1Y)
132,4
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Adaptive Biotechnologies Corporation
ADPT
|
|
|
||
|
Revenue Growth (5Y)
15,7
(≥ 15,0)
Revenue Growth (1Y)
54,8
(≥ 20,0)
Debt/Equity
1,3
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
PDD Holdings Inc.
PDD
|
|
|
||
|
Revenue Growth (5Y)
60,4
(≥ 15,0)
Revenue Growth (1Y)
59,0
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Arçelik Anonim Sirketi
ACKAY
|
|
|
||
|
Revenue Growth (5Y)
69,9
(≥ 15,0)
Revenue Growth (1Y)
32,7
(≥ 20,0)
Debt/Equity
3,5
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Enka Insaat ve Sanayi A.S.
EKIVF
|
|
|
||
|
Revenue Growth (5Y)
57,0
(≥ 15,0)
Revenue Growth (1Y)
55,7
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Japan Airport Terminal Co., Ltd.
JTTRY
|
|
|
||
|
Revenue Growth (5Y)
50,5
(≥ 15,0)
Revenue Growth (1Y)
24,1
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
Relay Therapeutics, Inc.
RLAY
|
|
|
||
|
Revenue Growth (5Y)
50,1
(≥ 15,0)
Revenue Growth (1Y)
53,4
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Wise plc
WIZEY
|
|
|
||
|
Revenue Growth (5Y)
43,9
(≥ 15,0)
Revenue Growth (1Y)
27,9
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
1,4
(0,0 – 2,0)
|
||||
Super Micro Computer, Inc.
SMCI
|
|
|
||
|
Revenue Growth (5Y)
57,7
(≥ 15,0)
Revenue Growth (1Y)
46,6
(≥ 20,0)
Debt/Equity
0,8
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Zinzino AB (publ)
ZNZNF
|
|
|
||
|
Revenue Growth (5Y)
24,7
(≥ 15,0)
Revenue Growth (1Y)
72,6
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Ford Otomotiv Sanayi A.S.
FOVSY
|
|
|
||
|
Revenue Growth (5Y)
84,9
(≥ 15,0)
Revenue Growth (1Y)
39,6
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Técnicas Reunidas, S.A.
TNISF
|
|
|
||
|
Revenue Growth (5Y)
23,2
(≥ 15,0)
Revenue Growth (1Y)
45,2
(≥ 20,0)
Debt/Equity
1,6
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Nova Ltd.
NVMI
|
|
|
||
|
Revenue Growth (5Y)
20,6
(≥ 15,0)
Revenue Growth (1Y)
31,0
(≥ 20,0)
Debt/Equity
0,7
(0,0 – 5,0)
PEG Ratio
1,0
(0,0 – 2,0)
|
||||
TransMedics Group, Inc.
TMDX
|
|
|
||
|
Revenue Growth (5Y)
111,5
(≥ 15,0)
Revenue Growth (1Y)
37,1
(≥ 20,0)
Debt/Equity
1,0
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Advantest Corporation
ADTTF
|
|
|
||
|
Revenue Growth (5Y)
25,7
(≥ 15,0)
Revenue Growth (1Y)
60,3
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Luckin Coffee Inc.
LKNCY
|
|
|
||
|
Revenue Growth (5Y)
57,1
(≥ 15,0)
Revenue Growth (1Y)
37,1
(≥ 20,0)
Debt/Equity
0,7
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Camurus AB (publ)
CAMRF
|
|
|
||
|
Revenue Growth (5Y)
39,4
(≥ 15,0)
Revenue Growth (1Y)
21,3
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,7
(0,0 – 2,0)
|
||||
Badger Infrastructure Solutions Ltd.
BDGIF
|
|
|
||
|
Revenue Growth (5Y)
19,3
(≥ 15,0)
Revenue Growth (1Y)
55,9
(≥ 20,0)
Debt/Equity
0,9
(0,0 – 5,0)
PEG Ratio
0,4
(0,0 – 2,0)
|
||||
Dave Inc.
DAVE
|
|
|
||
|
Revenue Growth (5Y)
35,2
(≥ 15,0)
Revenue Growth (1Y)
47,5
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Immunocore Holdings plc
IMCR
|
|
|
||
|
Revenue Growth (5Y)
69,0
(≥ 15,0)
Revenue Growth (1Y)
20,1
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
1,4
(0,0 – 2,0)
|
||||
Comfort Systems USA, Inc.
FIX
|
|
|
||
|
Revenue Growth (5Y)
31,2
(≥ 15,0)
Revenue Growth (1Y)
29,5
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
Confluent, Inc.
CFLT
|
|
|
||
|
Revenue Growth (5Y)
31,7
(≥ 15,0)
Revenue Growth (1Y)
21,1
(≥ 20,0)
Debt/Equity
1,0
(0,0 – 5,0)
PEG Ratio
1,8
(0,0 – 2,0)
|
||||
The Pennant Group, Inc.
PNTG
|
|
|
||
|
Revenue Growth (5Y)
21,2
(≥ 15,0)
Revenue Growth (1Y)
36,3
(≥ 20,0)
Debt/Equity
1,4
(0,0 – 5,0)
PEG Ratio
1,7
(0,0 – 2,0)
|
||||
Taiwan Semiconductor Manufacturing Company Limited
TSM
|
|
|
||
|
Revenue Growth (5Y)
24,8
(≥ 15,0)
Revenue Growth (1Y)
33,0
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,6
(0,0 – 2,0)
|
||||
Raksul Inc.
RKSLF
|
|
|
||
|
Revenue Growth (5Y)
19,6
(≥ 15,0)
Revenue Growth (1Y)
21,2
(≥ 20,0)
Debt/Equity
1,1
(0,0 – 5,0)
PEG Ratio
1,2
(0,0 – 2,0)
|
||||
Galapagos N.V.
GLPG
|
|
|
||
|
Revenue Growth (5Y)
23,1
(≥ 15,0)
Revenue Growth (1Y)
303,5
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,0
(0,0 – 2,0)
|
||||
Neurocrine Biosciences, Inc.
NBIX
|
|
|
||
|
Revenue Growth (5Y)
26,0
(≥ 15,0)
Revenue Growth (1Y)
21,5
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,7
(0,0 – 2,0)
|
||||
monday.com Ltd.
MNDY
|
|
|
||
|
Revenue Growth (5Y)
41,4
(≥ 15,0)
Revenue Growth (1Y)
26,8
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
Flywire Corporation
FLYW
|
|
|
||
|
Revenue Growth (5Y)
32,7
(≥ 15,0)
Revenue Growth (1Y)
26,6
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
Duolingo, Inc.
DUOL
|
|
|
||
|
Revenue Growth (5Y)
42,6
(≥ 15,0)
Revenue Growth (1Y)
38,7
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Twist Bioscience Corporation
TWST
|
|
|
||
|
Revenue Growth (5Y)
29,9
(≥ 15,0)
Revenue Growth (1Y)
20,3
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
0,3
(0,0 – 2,0)
|
||||
DoorDash, Inc.
DASH
|
|
|
||
|
Revenue Growth (5Y)
29,4
(≥ 15,0)
Revenue Growth (1Y)
27,9
(≥ 20,0)
Debt/Equity
0,4
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
Kraken Robotics Inc.
KRKNF
|
|
|
||
|
Revenue Growth (5Y)
65,1
(≥ 15,0)
Revenue Growth (1Y)
31,2
(≥ 20,0)
Debt/Equity
0,2
(0,0 – 5,0)
PEG Ratio
0,1
(0,0 – 2,0)
|
||||
Saab AB (publ)
SAABY
|
|
|
||
|
Revenue Growth (5Y)
19,2
(≥ 15,0)
Revenue Growth (1Y)
24,2
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Redcare Pharmacy N.V.
SHPPF
|
|
|
||
|
Revenue Growth (5Y)
29,0
(≥ 15,0)
Revenue Growth (1Y)
24,0
(≥ 20,0)
Debt/Equity
0,9
(0,0 – 5,0)
PEG Ratio
2,0
(0,0 – 2,0)
|
||||
Harmony Biosciences Holdings, Inc.
HRMY
|
|
|
||
|
Revenue Growth (5Y)
29,9
(≥ 15,0)
Revenue Growth (1Y)
21,5
(≥ 20,0)
Debt/Equity
0,3
(0,0 – 5,0)
PEG Ratio
1,7
(0,0 – 2,0)
|
||||
SI-BONE, Inc.
SIBN
|
|
|
||
|
Revenue Growth (5Y)
22,2
(≥ 15,0)
Revenue Growth (1Y)
20,2
(≥ 20,0)
Debt/Equity
0,0
(0,0 – 5,0)
PEG Ratio
1,1
(0,0 – 2,0)
|
||||
Recursion Pharmaceuticals, Inc.
RXRX
|
|
|
||
|
Revenue Growth (5Y)
65,3
(≥ 15,0)
Revenue Growth (1Y)
26,9
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
0,2
(0,0 – 2,0)
|
||||
BayCurrent Consulting, Inc.
BYCRF
|
|
|
||
|
Revenue Growth (5Y)
28,3
(≥ 15,0)
Revenue Growth (1Y)
23,6
(≥ 20,0)
Debt/Equity
0,1
(0,0 – 5,0)
PEG Ratio
1,7
(0,0 – 2,0)
|
||||